Positive Data in C. Difficile Send Optimer Shares Soaring

Much awaited data from Optimer Pharmaceuticals Inc.'s pivotal study of macrocyclic antibiotic OPT-80 in the troublesome Clostridium difficile-based infection space did not disappoint investors, as top-line results showed that the drug not only met the primary endpoint of noninferiority compared to Vancocin but actually demonstrated superior activity to the marketed drug. (BioWorld Today)